Rosacea is a chronic inflammatory disease with transient and non-transient redness as key characteristics. Brimonidine is a selective a2-adrenergic receptor (AR) agonist approved for persistent facial erythema of rosacea based on significant efficacy and good safety data. The majority of patients treated with brimonidine report a benefit; however, there have been sporadic reports of worsening erythema after the initial response. A group of dermatologists, receptor physiology, and neuroimmunology scientists met to explore potential mechanisms contributing to side effects as well as differences in efficacy. We propose the following could 
sporadic reports of worsening erythema after the initial response. A group of dermatologists, receptor physiology, and neuroimmunology scientists met to explore potential mechanisms contributing to side effects as well as differences in efficacy. We propose the following could contribute to erythema after application: (1) Topical brimonidine gel 0.33% is approved to treat rosacea-associated redness [12, 13] . This agent selectively binds a 2 -adrenergic receptors (ARs) on vascular smooth muscle resulting in local transient vasoconstriction following topical application. Approximately 80% of patients treated with brimonidine report redness relief [14] . As the effects of brimonidine wear off (typically 10-12 h after application), erythema is expected to slowly return to baseline. In post-marketing experience, there were some reports of a transient worsening erythema rather than a return to baseline levels manifesting as [15] [16] [17] :
• Paradoxical erythema-redness appearing within 6 h after the application of brimonidine (can be worse than baseline).
• Exaggerated recurrence of erythemaredness greater than baseline that occurs as therapy wears off (10-12 h post-application).
• Allergic contact dermatitis-redness (usually accompanied by other signs, such as eczema and pruritus) occurring several months after the initiation of therapy.
Side effects were not reported in publications of the pivotal clinical trials as ''paradoxical erythema;'' however, Holmes et al. [18] conducted an analysis of adverse events and stated 3.6% of subjects reported erythema and 1.8% flushing during the phase 3 study; in the long-term study, 9.1% of subjects had flushing and 6.5% had erythema. Tanghetti et al. [15] estimated that 10-20% of patients are at risk for worsening of redness. Jackson et al. [19] state ''in our clinics, approximately 4-15% of patients have complained of worsening erythema or flushing,'' adding that while this led to discontinuation of drug for some, many patients were able to successfully continue treatment, because ''worsening of erythema was only temporary and not a daily issue.'' Furthermore, they noted that erythema typically occurred during the initiation of therapy and subsided with regular use [19] . In response to a case report published in 2016, Tanghetti agreed, noting ''Once the paradoxical erythema subsided, some patients were able to resume therapy without recurrence of this problem'' [55].
We discuss physiologic mechanisms that may contribute to worsening erythema (Fig. 1) .
In our opinion, the most likely candidates are:
• Local inflammation with perivascular inflammatory cells bearing increased or modified brimonidine-responsive ARs, leading to increased drug effect to release mediators and produce sustained vasodilatation (Fig. 1 ).
• High concentration of brimonidine in the skin (e.g., due to skin barrier dysfunction). Brimonidine may penetrate in higher concentrations to endothelium and nerve terminals to cause vasodilatation (Figs. 1, 2).
• Abnormal saturation effects and inhibited release of norepinephrine (NE) from sympathetic nerve terminals due to the • Genetic polymorphism(s) for genes increase the affinity of brimonidine to the receptor, resulting in increased smooth muscle responses and sustained vasodilation.
Compliance with Ethics Guidelines
This article does not contain any new studies with human or animal subjects performed by any of the authors. [20] . The function of a-ARs in the skin is primarily to regulate blood flow through vasoconstriction following catecholamine binding to receptors on vascular smooth muscle, where the mobilization of calcium stores results in muscle cell contraction. Detailed molecular mechanisms of ARs are described elsewhere [21] .
BRIEF REVIEW OF ADRENERGIC RECEPTOR FUNCTIONS

Factors that Affect Receptor Function
a 2 Receptors a-ARs are divided into a 1 and a 2 subtypes. The relative contribution of a 1 and a 2 subtypes in subcutaneous vessels can vary with location, receptor density, local NE concentration, and temperature [20, 22, 23] . The density of arterial 
Receptor Expression on Immune Cells
Finally, several immune cell subsets present in the skin express a 1 -and a 2 -ARs. Brimonidine is a selective a 2A -AR agonist, but it exhibits a reduced affinity for a 2C -and a 1A -ARs as well [24] . Binding to the more recently characterized a 1D subtype was not tested, but may also occur when brimonidine is present at high concentrations. The effect of brimonidine on other receptors or cell types might be concentration dependent, and a spillover effect after saturation of the a 2A -AR on vascular smooth muscle could occur.
Increased local concentrations ('spillover effect') may allow brimonidine to act on at least one endothelial receptor (a 2A -AR and other subtypes), thereby promoting NO-mediated vasodilation. Brimonidine may also act on To minimize the potential for complications related to concentration and skin barrier function, we agree with the recommendations by Tanghetti et al. [15] to set realistic patient expectations by providing clear education, to teach patients to apply the medication in a very thin layer initially, and to make the first trial of medication on a day when the patient is able to observe the effect in privacy. An NF-kB binding site in the promoter region of G protein receptor kinase (GRKs) could be involved in shifting GPCR signaling [41] . These kinases are well known to regulate GPCR cell function, including receptor internalization and desensitization, thereby leading to reduced receptor numbers (by downregulation) as well as alternate signaling via recruitment of b-arrestin [42] . Moreover, shifts in AR signaling have been linked to the induction of inflammation by increasing NF-kB levels [43] [44] [45] [46] [47] [48] [49] [50] [51] . This could be a possible mechanism for the adverse rebound effect observed in some patients using brimonidine. Best results may be obtained when rosacea-associated inflammation is managed using the traditional rosacea treatments in conjunction with brimonidine therapy. Using brimonidine to reduce the overall erythema can unmask redness from inflammatory lesions, which is unpalatable for patients. It may also be useful to educate patients about overall facial erythema, telangiectasias, and perilesional erythema [15] . This potential mechanism also underscores the prudence of advising patients to make the first trial of medication on the weekend or a day when the patient can be comfortable even in the unlikely event that worsening erythema occurs [15] .
Impact of Inflammation
Impact of Genetic Polymorphisms
SUMMARY AND CONCLUSIONS
Brimonidine has proven strong vasoconstrictive effects on a 2 -ARs of vessels and-to a lesser extent-on a 1 -ARs [24] . In rosacea, ARs on other tissues-such as endothelium, presynaptic adrenergic nerve terminals, and immune cells-may also promote vasodilation. Skin reactivity to adrenergic agonists may be influenced by a complex system of activation and inhibition, systemic factors, such as epinephrine/NE levels, local tissue factors clinicians to educate patients who should be taught to start with a very thin layer of medication and to use other strategies that can optimize brimonidine therapy [15] . 
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